|
May 1
|
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
|
|
Apr 24
|
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
|
|
Apr 8
|
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
|
|
Apr 8
|
Supernus Provides Regulatory Update for SPN-830
|
|
Mar 6
|
Supernus to Participate in Two Upcoming Investor Conferences
|
|
Mar 5
|
11 Best Small Cap Pharma Stocks to Invest In
|
|
Jan 14
|
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
|
|
Dec 19
|
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
|
|
Dec 4
|
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 8.7% CAGR over the last three years
|
|
Oct 9
|
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
|
|
Sep 27
|
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
|
|
Sep 10
|
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
|
|
Aug 21
|
Bethany L. Sensenig Joins Supernus’ Board of Directors
|
|
Apr 25
|
Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023
|